These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9212845)
1. Concomitant p53 mutation and MYCN amplification in neuroblastoma. Manhani R; Cristofani LM; Odone Filho V; Bendit I Med Pediatr Oncol; 1997 Sep; 29(3):206-7. PubMed ID: 9212845 [TBL] [Abstract][Full Text] [Related]
2. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification. Chen B; Jhanwar SC; Ladanyi M Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma). Lorenzana AN; Zielenska M; Thorner P; Gerrie B; Weitzman S; Squire J Pediatr Pathol Lab Med; 1997; 17(6):875-83. PubMed ID: 9353827 [TBL] [Abstract][Full Text] [Related]
4. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128 [TBL] [Abstract][Full Text] [Related]
5. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Imamura J; Bartram CR; Berthold F; Harms D; Nakamura H; Koeffler HP Cancer Res; 1993 Sep; 53(17):4053-8. PubMed ID: 8358734 [TBL] [Abstract][Full Text] [Related]
6. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
7. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Manohar CF; Salwen HR; Brodeur GM; Cohn SL Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036 [TBL] [Abstract][Full Text] [Related]
8. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Valent A; Bénard J; Clausse B; Barrois M; Valteau-Couanet D; Terrier-Lacombe MJ; Spengler B; Bernheim A Am J Pathol; 2001 May; 158(5):1579-84. PubMed ID: 11337354 [TBL] [Abstract][Full Text] [Related]
9. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849 [TBL] [Abstract][Full Text] [Related]
10. Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction. Boerner S; Squire J; Thorner P; McKenna G; Zielenska M Pediatr Pathol; 1994; 14(5):823-32. PubMed ID: 7808981 [TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues. Misra DN; Dickman PS; Yunis EJ Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703 [TBL] [Abstract][Full Text] [Related]
13. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience. Telford DJ; Kavallaris M; White L; Norris MD; Brian MJ; Stewart BW J Paediatr Child Health; 1992 Feb; 28(1):58-63. PubMed ID: 1554517 [TBL] [Abstract][Full Text] [Related]
14. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R; Hero B; Skowron M; Ernestus K; Berthold F Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958 [TBL] [Abstract][Full Text] [Related]
15. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)]. Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442 [TBL] [Abstract][Full Text] [Related]
16. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma. Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278 [TBL] [Abstract][Full Text] [Related]
17. Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients. Brack T; Scholz RB; Milde-Langosch K; Heinsohn S; Löning T; Kabisch H Cancer Detect Prev; 1992; 16(3):185-92. PubMed ID: 1458508 [TBL] [Abstract][Full Text] [Related]
18. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152 [TBL] [Abstract][Full Text] [Related]
19. MYCN protein expression as a predictor of neuroblastoma prognosis. Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553 [TBL] [Abstract][Full Text] [Related]
20. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]